

TCIMAIL

number **176**



CONTENTS


2 Research Article

- DABCO-*bis*(sulfur dioxide), DABSO, as a Source of Sulfur Dioxide in Transition Metal-Catalyzed Reactions

Michael C. Willis
Professor, Department of Chemistry,
University of Oxford, Chemistry Research Laboratory

13 New Products Information :

- Highly Regioselective Organic Semiconducting Polymer: P3HT
- Non-Aqueous Redox Flow Battery Material with High Current Density: MEEPT
- Lead Acetate Anhydrous Forming Perovskite under Anhydrous Condition
- Ready-to-use 4-Nitrophenyl Phosphate Solution for ELISA
- Anti- α Gal Polyclonal Antibody that can Detect the α Gal Epitope (Gal α 1-3Gal)
- OCT4 Activator
- AMP-Activated Protein Kinase (AMPK) Inhibitor



DABCO-*bis*(sulfur dioxide), DABSO, as a Source of Sulfur Dioxide in Transition Metal-Catalyzed Reactions

Michael C. Willis

Department of Chemistry, University of Oxford, Chemistry Research Laboratory,
Mansfield Road, Oxford, OX1 3TA, UK
Email: michael.willis@chem.ox.ac.uk

Abstract: The *bis*-adduct of DABCO with sulfur dioxide, DABSO, has been shown to function as an effective surrogate for gaseous sulfur dioxide. DABSO is a stable, solid reagent. The use of DABSO has allowed the first efficient transition metal-catalyzed cross-coupling type reactions of sulfur dioxide to be achieved. Early reactions employed palladium catalysts in combination with aryl iodides and *N,N*-dialkyl hydrazines, to deliver *N*-aminosulfonamides as products. More recently, alternative aryl substrates such as aryl bromides and aryl boronic acids have been employed, and products such as sulfones and sulfonyl fluorides can now be prepared in an efficient manner. In addition to palladium, reactions have been reported that use copper, cobalt and iridium catalysts. This review considers the catalytic reactions that have been developed using DABSO as a reagent, and is structured by type of catalyst used, and further by the type of product obtained.

Keywords: sulfur dioxide, catalysis, sulfonamide, sulfone, transition metal

1. Introduction

Sulfur dioxide has a long history of use in organic synthesis as both a reagent and solvent. Pericyclic reactions, including cheletropic additions and ene reactions, as well as the combination with preformed organometallic reagents such as organolithiums and Grignard reagents, are two examples of the transformations for which sulfur dioxide is well known.¹ Despite an extensive literature covering these and related reactions, there were very few examples in the literature of sulfur dioxide being used as a reagent in combination with transition metal catalysts.² Notwithstanding the lack of literature precedent, we were

interested in the development of cross-coupling type reactions in which sulfur dioxide would be incorporated. Our key breakthrough was the discovery that the *bis*-adduct of DABCO with sulfur dioxide, which we have named DABSO, functions as an effective surrogate³ reagent for sulfur dioxide gas (Figure 1).⁴ DABSO is a colorless crystalline solid that decomposes at 200 °C (DSC). DABSO is air stable and easily handled. It is usually stored under inert gas at room temperature.⁵ Although we have shown that DABSO can function as a SO₂-surrogate in combination with preformed organometallics,⁶ the focus of this review is the use of DABSO in transition metal catalysis.




Figure 1.


2. Palladium-Catalyzed Reactions

2-1. Sulfonamide Synthesis


The sulfonamide functional group features in a wide range of pharmaceuticals and agrochemicals, and as such these important motifs were the first class of compounds that we targeted. The successful chemistry allowed the union of aryl iodides, sulfur dioxide (provided from the reagent DABSO) and *N,N*-dialkylhydrazines, using a palladium(0) catalyst, to provide *N*-aminosulfonamides as the products.⁷ Selected examples are shown in Scheme 1; variation of the aryl iodide component was readily achieved, and a broad range of functional groups could be tolerated. Heteroaryl iodides were also competent substrates, as were alkenyl iodides. The *N*-nucleophile was limited to *N,N*-dialkylhydrazines, but variation of the alkyl substituents of

the hydrazine was possible. All of the reactions were achieved using a catalyst generated from $P(t\text{-Bu})_3$ (used as its HBF_4 salt)⁸ and $\text{Pd}(\text{OAc})_2$. The majority of reactions required only 0.6 equivalents of DABSO, demonstrating the excellent uptake of SO_2 during these reactions. Although this chemistry is limited in the scope of *N*-nucleophiles that can be employed, it does represent the first example of an efficient three-component cross-coupling type reaction that employs sulfur dioxide.

Access to the parent sulfonamides using this chemistry was possible if *N,N*-dibenzylhydrazine was used as the *N*-nucleophile. The initially formed *N*-aminosulfonamide **1** was treated with hydrogen gas over a $\text{Pd}(\text{OH})_2$ catalyst in acetone as solvent. The *in situ* generated hydrazone **2** was then treated with zinc in acetic acid to provide the parent sulfonamide **3**.^{7b}



Scheme 1. Palladium-catalyzed *N*-aminosulfonamide synthesis from aryl iodides, DABSO and *N,N*-dialkylhydrazines





Scheme 2. Parent sulfonamide synthesis using *N,N*-dibenzylhydrazine as the nucleophile

Literature dating from 1957 had shown that *N*-aminosulfonamides can function as precursors to sulfinate salts. For example, when *N,N,N*-trialkylaminosulfonamide **4** was treated with an alkoxide base in isopropanol, sulfinate **5** was generated in good yield (Scheme 3).⁹

We were able to develop a version of this process that was applicable to the type of aminosulfonamides produced in Scheme 2. For example, following treatment of aminosulfonamide **6** with K_2CO_3 and two equivalents of *BnBr*, sulfone **7** was obtained in 92% yield.¹⁰ The reactions proceed by initial alkylation of the aminosulfonamide *N*-atom, followed by deprotonation and elimination to generate an intermediate sulfinate and hydrazone byproduct **8**; the sulfinate salt reacts with the excess benzyl bromide to provide the desired sulfone.

This protocol could be extended to a one-pot process whereby the palladium-catalysed aminosulfonamide synthesis was combined with sulfinate formation/arylation. For example, an alkenyl iodide substrate provided sulfone **9**, while an aryl iodide substrate, in combination with an epoxide electrophile for the second step, provide β -hydroxysulfone **10**.

The Wu group at Fudan University has made significant contributions to the use of DABSO in synthesis. One of their first contributions was to show that aryl nonaflates (perfluorobutanesulfonates) could be used as substrates in place of aryl iodides in the synthesis *N*-aminosulfonamides.¹¹ The reactions used a modified catalyst system in which Xantphos was employed as the supporting ligand (Scheme 4, eq 1). This is an important extension as it allows phenols to be considered as





substrates for these reactions. The same group also demonstrated that aryl boronic acids could be employed as substrates (Scheme 4, eq 2).¹² This change to boronic acid substrates required the use of a Pd(II) catalyst and an oxidant, which was provided by an oxygen atmosphere. No phosphine ligand was required for these transformations. The Wu group demonstrated that an initial gold-catalyzed iodination, generating the iodoarene *in situ*, could be combined with the palladium-catalyzed aminosulfonylation, allowing simple arenes to function as the starting materials (Scheme 4, eq 3).¹³ It should be noted that this is a two-step, one-pot process. All three of the transformations shown in Scheme 3, in which the arene starting material is varied, are still limited to the use of *N,N*-dialkylhydrazines as the *N*-nucleophiles. The Wu group has also introduced the use of potassium metabisulfate ($K_2S_2O_5$) as an alternative sulfur dioxide surrogate.¹⁴ In their original report, aryl iodides were combined with $K_2S_2O_5$ and *N,N*-dialkylhydrazines using Pd(0) catalysis, to provide the expected *N*-aminosulfonamides.

The Wu group have been pioneers of the use of DABSO as a source of sulfur dioxide in radical-based processes, often under metal-free conditions. Although these reactions are beyond the scope of this review, their lead publication in this area is shown in Scheme 5.¹⁵ The reactions employ aryl diazonium salts as aryl radical precursors, which can be combined with DABSO and an *N,N*-dialkylhydrazine to deliver *N*-aminosulfonamides as products. Importantly, these reactions are conducted at room temperature. A control reaction, using a substrate that features a tethered alkene (**11**), proceeded *via* cyclisation, ultimately providing *N*-aminosulfonamide **12** as the product, thus confirming the presence of radical intermediates.


2-2. Sulfinate Formation

The palladium-catalyzed preparation of *N*-aminosulfonamides, introduced in Scheme 2, established that SO_2 could be introduced in cross-coupling type reactions. However, the limitations with respect to the *N*-nucleophile result in the formation of specialized, not generally useful, products. In order to deliver a reaction of more utility we targeted the direct formation of sulfinate salts. This was achieved by replacing the *N*-nucleophile used in Scheme 2 with a hydride source, with the use of isopropanol being most effective; the general process is shown in Scheme 6.¹⁶ Aryl iodides are combined with DABSO in isopropanol (this serves as both solvent and hydride source) using a Pd(0) catalyst generated from $Pd(OAc)_2$ and $PA_{d_2}Bu$, with triethylamine as a base. The resulting sulfinate (**13**), can then be combined with a broad range of electrophiles, for example an alkyl halide, to provide the corresponding sulfone (**14**). When performed on gram scale the catalyst loading could be reduced to 1 mol%. Good variation of the aryl iodide substrate was possible, and alkenyl as well as heteroaryl variants could also be used (Scheme 6). A related reaction, which uses $K_2S_2O_5$ as the SO_2 source and sodium formate as the reductant, has been reported by scientists at Pfizer in the US.¹⁷




The utility of sulfinate salts is that they can be combined with a variety of alternative electrophiles to provide a correspondingly broad range of products. Selected examples of this approach, using sulfinate **13**, are shown in Scheme 7; the use of an epoxide provides β -hydroxy sulfone **15**, nucleophilic aromatic substitution delivers aryl-heteroaryl sulfone **16**, and chlorination followed by amine addition provides sulfonamide **17**.¹⁶


Given the prevalence of sulfonamides in medicinal and agrochemistry, we wanted to adapt the sulfinate synthesis described above to provide a simple and efficient entry to these important functional groups. Accordingly, we adapted our earlier chemistry based on the use of pre-formed organometallic reagents,^{6d} and were able to show that treatment of the *in situ* catalytically generated sulfinate intermediates with an aqueous solution of the relevant amine and bleach (NaOCl), provides the corresponding sulfonamides in high yield (Scheme 8).¹⁸ The



Scheme 7. Catalytically generated sulfinate intermediates in synthesis



Scheme 8. Sulfonamide synthesis using *in situ* generated *N*-chloroamines





Scheme 9. The palladium-catalyzed preparation of sulfonyl fluorides from aryl halides

reactions proceed *via in situ* formation of the *N*-chloroamines. Broad variation of both the aryl iodide and amine component was possible, including the use of heteroaryl iodides, and well as amines bearing acid-sensitive functional groups. Amino acids could also be employed, and the corresponding sulfonamides were obtained with no erosion of enantiomeric excess.

The sulfinate syntheses shown in Schemes 6, 7, and 8 all employ (hetero)aryl iodide substrates. A re-evaluation of phosphine ligands allowed a new catalyst system, this time featuring the ligand AmPhos, to be used in combination with (hetero)aryl bromide substrates.¹⁹ In a collaboration with scientists at Pfizer, this chemistry was showcased in the synthesis of a range of sulfonyl fluorides (Scheme 9). The *in situ* generated sulfonates are treated with NFSI, which is a source of F⁺, and delivered the corresponding sulfonyl fluorides in good yields. Good variation of the aryl bromide was possible. Sulfonyl fluorides are important molecules for the design of covalent inhibitors, and as probe reagents in chemical biology applications; Scheme 9 also shows the preparation of several sulfonyl fluorides from halogenated pharmaceuticals, or pharmaceutical fragments that were prepared using this methodology.

To complement the Pd(0)-catalyzed sulfonylation procedures described above, we have also developed a Pd(II)-catalyzed protocol that employs aryl boronic acids as the substrates (Scheme 10).²⁰ The reaction conditions consist of Pd(OAc)₂ with tetrabutylammonium bromide (TBAB) in a methanol/dioxane solvent mixture at 80 °C. No phosphine ligands were required in the reactions. Complete conversion to sulfinate was achieved after just 30 minutes, at which point an electrophile could be added. As shown in Scheme 10, good variation of the starting aryl boronic acid, including heterocyclic variants was possible, and a variety of electrophiles could be introduced in the second step, allowing access to various sulfones as well as sulfonamides. A related transformation, which uses K₂S₂O₅ as the SO₂ source, has been reported by scientists at Pfizer in the US.²¹

The sulfonamide shown in Scheme 10 was prepared by the addition of an aqueous solution of the amine and NaOCl to the *in situ* generated sulfinate. The reaction proceeds *via* the *in situ* formation of the *N*-chloroamine which functions as an electrophilic amine component. Similar reactivity has been reported by Tu and co-workers, who used preformed *N*-benzoyloxyamines as electrophilic amine components in combination with a Cu(II) catalyst (Scheme 11).²²




3. Copper-Catalyzed Reactions

The Wang group were the first to report a copper-catalyzed process involving DABSO. They developed a variant of the aminosulfonamide synthesis shown in Scheme 1, but employed aryl triethoxysilanes as the substrates in combination with a Cu(II)-catalyst (Scheme 12).²³ Cu(OAc)₂ was employed as the catalyst, along with an oxygen atmosphere. The reactions were tolerant of a broad range of silanes, but the commercial availability of these reagents is limited. As with the related palladium-catalyzed reactions, the *N*-nucleophile is again limited to *N,N*-dialkylhydrazines.


The Wu group employed the same class of aryl substrate in a copper-catalyzed sulfone synthesis.²⁴ Their method involved the combination of aryl triethoxysilanes, DABSO, and an alkyl halide using Cu₂O as catalyst (Scheme 13).

The same group reported a copper-catalyzed preparation of benzothiophene-1,1-dioxides (Scheme 14). The chemistry involved the combination of *o*-alkynylboronic acids (**18**), with DABSO and a Cu(II) catalyst.²⁵ Reasonable variation of the substrate was possible, delivering the expected heterocycles in moderate to good yields.


Our laboratory has reported a Cu(I)-catalyzed synthesis of aryl sulfinates using aryl boronic acids as substrates (Scheme 15).²⁶ The chemistry employs the commercially available copper catalyst Cu(MeCN)₄BF₄ and relies on a 12 hour reaction to achieve complete sulfinato formation. Addition of a variety of electrophiles is possible, trapping the sulfinato, and providing sulfones, sulfonamides, and sulfonyl fluorides. This chemistry provides a copper variant of the palladium-catalyzed reactions presented in Scheme 10.



Scheme 12. The copper(II)-catalyzed preparation of *N*-aminosulfonamides using aryl triethoxysilanes




Scheme 13. The copper-catalyzed preparation of sulfones using aryl triethoxysilanes




Scheme 14. The copper-catalyzed synthesis of benzothiophene-1,1-dioxides

Our laboratory was also able to exploit copper-catalysis in developing the first examples of a sulfonylative Suzuki-Miyaura cross-coupling (Scheme 16).²⁶ The reactions allowed the direct combination of aryl boronic acids, aryl halides and sulfur dioxide (provided from DABSO), and employ the same commercial copper catalyst, this time partnered with the indicated bipyridine ligand. Good variation of both the aryl iodide and aryl boronic acid was possible, including the use of heteroaryl variants, as well as alkenyl examples. This chemistry represents the first sulfonylative variant of any classic cross-coupling process.


A copper-catalyzed direct sulfonamide synthesis has also been reported, and involves the coupling of aryl hydrazines, sulfur dioxide (from DABSO), and amines, using a CuBr catalyst and an air atmosphere (Scheme 17).²⁷ The chemistry involves the oxidative conversion of the aryl hydrazines to aryl radicals. This is a rare example of a direct sulfonamide synthesis, but is limited by the need to employ aryl hydrazines as the substrates.




Scheme 15. The copper(I)-catalyzed sulfonylation, and onwards to sulfones, sulfonamides and sulfonyl fluorides



Scheme 16. The copper(I)-catalyzed sulfonylative Suzuki-Miyaura cross-coupling



Scheme 17. The copper(I)-catalyzed sulfonamide synthesis employing aryl hydrazine substrates



Scheme 18. The copper(II)-catalyzed C-H sulfonylation of 8-aminoquinoline amides

The final copper-catalyzed DABSO-based reaction we will consider is a recent report from the Wu group, and involves the sulfonylation of an aryl C-H bond (Scheme 18).²⁸ The chemistry is radical based, and involves the coupling of a quinolinyl-derived amide (**19**) with DABSO and an aryl diazonium salt using a Cu(II) catalyst. The targeted C-H functionalization products, diaryl sulfones, are obtained in moderate yields.


4. Miscellaneous Metal Catalysts

Although palladium and copper catalysts provide the majority of examples of DABSO, and alternative SO₂-surrogates, use in synthesis, there are a handful of reports that employ different metal catalysts. For example, The Toste group, in collaboration with scientists at Pfizer, have demonstrated that Au(I) complexes are effective catalysts for the addition of sulfur dioxide to aryl boronic acids.²⁹ They utilized this reactivity in a one-pot sulfone synthesis (Scheme 19, eq 1). Note, K₂S₂O₅ is used as the SO₂-source. Recently, a Au(I)-carbene complex has also been used in a closely related system.³⁰ The same overall transformation can also be promoted using a cobalt complex.³¹ In this case, cobalt oxide is used in stoichiometric amounts, and promotes the union of aryl triethoxysilanes, DABSO and an alkyl halide (Scheme 19, eq 2).


The Wu group has reported a second aryl C-H sulfonylation protocol, this time employing an iron catalyst (Scheme 20).³² This radical process combines 2-naphthols, DABSO, and aryl diazonium salts, and delivers diaryl sulfone products in good yields. A simple FeCl₃ catalyst is employed. The final transformation we will consider is a recent report from the Wu group concerning thiophosphate synthesis. Aryl iodonium salts are used as the substrates and are combined with DABSO and diphenylphosphine oxide, in the presence of an iridium photocatalyst (Scheme 21).³³ Irradiation with visible light results in formation of the thiophosphonate **20**. This is an unusual example of DABSO use in which the SO₂ is reduced during the transformations.

5. Conclusions


The advent of DABSO (and other reagents) as an effective surrogate for sulfur dioxide gas has allowed the development of a range of transition metal catalyzed reactions that result in sulfur dioxide incorporation. Although early examples deliver rather esoteric products, more recent reactions deliver synthetically useful products. Palladium and copper based catalysts dominate the reactions that have been reported, but recent advances suggest that alternative metals could provide useful, and different, reactivity.



Scheme 19. Gold and cobalt mediated sulfone syntheses



Scheme 20. Iron-catalyzed naphthol sulfonylation



Scheme 21. Iridium-catalyzed thiophosphonate synthesis

References

1. A. S. Deeming, E. J. Emmett, C. S. Richards-Taylor, M. C. Willis, *Synthesis* **2014**, 46, 2701.
2. a) H. S. Klein, *J. Chem. Soc. Chem. Commun.* **1968**, 377. b) W. Keim, J. Herwig, *J. Chem. Soc., Chem. Commun.* **1993**, 1592. c) U. M. Dzhemilev, R. V. Kunakova, *J. Organomet. Chem.* **1993**, 455, 1. d) G. Pelzer, W. Keim, *J. Mol. Catal. A: Chem.* **1999**, 139, 235.
3. E. J. Emmett, M. C. Willis, *Asian J. Org. Chem.* **2015**, 4, 602.
4. H. Woolven, C. González-Rodríguez, I. Marco, A. L. Thompson, M. C. Willis, *Org. Lett.* **2011**, 13, 4876.
5. a) A. S. Deeming, M. C. Willis, In *Encyclopedia of Reagents for Organic Synthesis*, John Wiley & Sons, **2001**. b) L. Martial, *Synlett* **2013**, 24, 1595.
6. a) E. J. Emmett, B. R. Hayter, M. C. Willis, *Angew. Chem. Int. Ed.* **2013**, 52, 12679. b) A. S. Deeming, C. J. Russell, A. J. Hennessy, M. C. Willis, *Org. Lett.* **2014**, 16, 150. c) B. N. Rocke, K. B. Bahnck, M. Herr, S. Lavergne, V. Mascitti, C. Perreault, J. Polivkova, A. Shavnya, *Org. Lett.* **2014**, 16, 154. d) A. S. Deeming, C. J. Russell, M. C. Willis, *Angew. Chem. Int. Ed.* **2015**, 54, 1168. e) D. C. Lenstra, V. Vedovato, E. F. Flegeau, J. Maydom, M. C. Willis, *Org. Lett.* **2016**, 18, 2086.
7. a) B. Nguyen, E. J. Emmett, M. C. Willis, *J. Am. Chem. Soc.* **2010**, 132, 16372. b) E. J. Emmett, C. S. Richards-Taylor, B. Nguyen, A. Garcia-Rubia, B. R. Hayter, M. C. Willis, *Org. Biomol. Chem.* **2012**, 10, 4007.
8. M. R. Netherton, G. C. Fu, *Org. Lett.* **2001**, 3, 4295.
9. A. Dornow, W. Bartsch, *Justus Liebigs Annalen der Chemie* **1957**, 602, 23.
10. C. S. Richards-Taylor, D. C. Blakemore, M. C. Willis, *Chem. Sci.* **2014**, 5, 222.
11. Y. An, H. Xia, J. Wu, *Org. Biomol. Chem.* **2016**, 14, 1665.
12. S. Ye, J. Wu, *Chem. Commun.* **2012**, 48, 7753.
13. S. Ye, H. Wang, Q. Xiao, Q. Ding, J. Wu, *Adv. Synth. Catal.* **2014**, 356, 3225.
14. S. Ye, J. Wu, *Chem. Commun.* **2012**, 48, 10037.
15. D. Zheng, Y. An, Z. Li, J. Wu, *Angew. Chem. Int. Ed.* **2014**, 53, 2451.
16. E. J. Emmett, B. R. Hayter, M. C. Willis, *Angew. Chem. Int. Ed.* **2014**, 53, 10204.
17. A. Shavnya, S. B. Coffey, A. C. Smith, V. Mascitti, *Org. Lett.* **2013**, 15, 6226.
18. E. F. Flegeau, J. M. Harrison, M. C. Willis, *Synlett* **2016**, 27, 101.
19. A. T. Davies, J. M. Curto, S. W. Bagley, M. C. Willis, *Chem. Sci.* **2017**, 8, 1233.
20. A. S. Deeming, C. J. Russell, M. C. Willis, *Angew. Chem. Int. Ed.* **2016**, 55, 747.
21. A. Shavnya, K. D. Hesp, V. Mascitti, A. C. Smith, *Angew. Chem. Int. Ed.* **2015**, 54, 13571.
22. H. Zhu, Y. Shen, Q. Deng, C. Huang, T. Tu, *Chem. Asian J.* **2017**, 12, 706.
23. X. Wang, L. Xue, Z. Wang, *Org. Lett.* **2014**, 16, 4056.
24. D. Zheng, R. Mao, Z. Li, J. Wu, *Org. Chem. Front.* **2016**, 3, 359.
25. R. Mao, D. Zheng, H. Xia, J. Wu, *Org. Chem. Front.* **2016**, 3, 693.
26. Y. Chen, M. C. Willis, *Chem. Sci.* **2017**, 8, 3249.
27. B. Du, Y. Wang, W. Sha, P. Qian, H. Mei, J. Han, Y. Pan, *Asian J. Org. Chem.* **2017**, 6, 153.
28. H. Xia, Y. An, X. Zeng, J. Wu, *Org. Chem. Front.* **2017**, in press (DOI: 10.1039/C7QO00866J).
29. M. W. Johnson, S. W. Bagley, N. P. Mankad, R. G. Bergman, V. Mascitti, F. D. Toste, *Angew. Chem. Int. Ed.* **2014**, 53, 4404.
30. H. Zhu, Y. Shen, Q. Deng, J. Chen, T. Tu, *ACS Catal.* **2017**, 7, 4655.
31. D. Zheng, M. Chen, L. Yao, J. Wu, *Org. Chem. Front.* **2016**, 3, 985.
32. K. Zhou, M. Chen, L. Yao, J. Wu, *Org. Chem. Front.* **2018**, in press (DOI:10.1039/C7QO00811B).
33. X. Gong, J. Chen, J. Liu, J. Wu, *Org. Chem. Front.* **2017**, 4, 2221.

Introduction of the author:



Michael C. Willis


Professor, Ph.D.

Department of Chemistry, University of Oxford, Chemistry Research Laboratory

Michael Willis is a Professor of Chemistry at the University of Oxford. He received his undergraduate education at Imperial College London, and his Ph.D. from the University of Cambridge working with Prof. Steven Ley. After a postdoctoral stay with Prof. David Evans at Harvard University, he was appointed to a lectureship at the University of Bath in November 1997. In January 2007 he moved to the University of Oxford, where he is now a Professor of Chemistry and a Fellow of Lincoln College. His group's research interests are based on the development and application of new catalytic processes for organic synthesis, with a particular interest in transition metal catalysis. His work has been recognized by the award of recent prizes, including the Royal Society of Chemistry's 2014 Catalysis in Organic Chemistry Award, and the 2015 Pfizer, AstraZeneca, Syngenta, Process Chemistry Research Award.


TCI Related Products

B3960 DABSO [= Bis(sulfur Dioxide)-1,4-diazabicyclo[2.2.2]octane Adduct] 1g 5g




DABSO


D0134	DABCO [= 1,4-Diazabicyclo[2.2.2]octane]	25g	100g	500g
P2480	Potassium Disulfite		25g	500g
T0054	TBAB (= Tetrabutylammonium Bromide)	25g	100g	500g
F0335	NFSI [= <i>N</i> -Fluorobenzenesulfonimide] [Fluorinating Reagent]		5g	25g
C2204	Cesium Fluoride		25g	100g
A1424	Palladium(II) Acetate		1g	5g



DABCO




TBAB




NFSI


P2161	Palladium(II) Acetate (Purified)			1g
T2666	Tetrakis(acetonitrile)copper(I) Tetrafluoroborate	1g	5g	25g
C2346	Copper(II) Acetate Monohydrate		25g	500g
B2709	Xantphos [= 4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene]	1g	5g	25g
D4531	Amphos [= (4-Dimethylaminophenyl)di- <i>tert</i> -butylphosphine]		1g	5g
D5038	XPhos [= 2-Dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl]		1g	5g
D3886	4,4'-Dimethoxy-2,2'-bipyridyl		1g	5g
T1946	Ir(ppy) ₃ [= Tris(2-phenylpyridinato)iridium(III)] (purified by sublimation)			200mg
P1528	Pearlman's Catalyst [= Palladium Hydroxide (contains Pd, PdO) on Carbon] (wetted with ca. 50% Water)		10g	50g




Xantphos



Amphos



XPhos



Ir(ppy)₃

Highly Regioselective Organic Semiconducting Polymer: P3HT

P2513 Poly(3-hexylthiophene-2,5-diyl) (Mn.=ca. 40,000) (regioregular) (1) 100mg 500mg

Poly(3-hexylthiophene) (P3HT, **1**) is widely useful in organic electronics research fields, and is a representative material of soluble organic semiconducting polymers. The performance of electronic materials is typically dependent on the quality of the material. Among them, purity and molecular weight are important factors for the material performance. **1** was synthesized by a direct arylation polymerization (DARp)^{1,2} and features a highly regioselective structure with a consistent average molecular weight and polydispersity index. In addition, **1** is useful for solution process-able organic solar cells,^{3,4} perovskite solar cells,⁵ and organic transistor research,⁶ due in part to its high solubility.




Figure 1. Organic Photovoltaics (OPV)

Figure 2. Perovskite Solar Cell (PSC)

Figure 3. Organic Transistor (OFET)

This material was produced by collaboration with Prof. Fumiyuki Ozawa at Institute for Chemical Research, Kyoto University.


References

- 1) Palladium-catalyzed dehydrohalogenative polycondensation of 2-bromo-3-hexylthiophene: An efficient approach to head-to-tail poly(3-hexylthiophene)
Q. Wang, R. Takita, Y. Kikuzaki, F. Ozawa, *J. Am. Chem. Soc.* **2010**, *132*, 11420.
- 2) Structural analysis of poly(3-hexylthiophene) prepared via direct heteroarylation polymerization
J.-R. Pouliot, M. Wakioka, F. Ozawa, Y. Li, M. Leclerc, *Macromol. Chem. Phys.* **2016**, *217*, 1493.
- 3) A review of recent plasmonic nanoparticles incorporated P3HT: PCBM Organic thin film solar cells
E. L. Lim, C. C. Yap, M. A. M. Teridi, C. H. Teh, A. R. M. Yusoff, M. H. H. Jumali, *Org. Electron.* **2016**, *36*, 12.
- 4) Poly(3-hexylthiophene): Synthetic methodologies and properties in bulk heterojunction solar cells
A. Marrocchi, D. Lanari, A. Facchetti, L. Vaccaro, *Energy Environ. Sci.* **2012**, *5*, 8457.
- 5) Hole-transport materials for perovskite solar cells
L. Calió, S. Kazim, M. Grätzel, S. Ahmad, *Angew. Chem. Int. Ed.* **2016**, *55*, 14522.
- 6) 25th Anniversary article: Organic field-effect transistors: The path beyond amorphous silicon
H. Sirringhaus, *Adv. Mater.* **2014**, *26*, 1319.

Non-Aqueous Redox Flow Battery Material with High Current Density: MEEPT

M3068 10-[2-(2-Methoxyethoxy)ethyl]-10H-phenothiazine (1)

10g



MEEPT (1)

Odom *et al.* have recently developed 10-[2-(2-methoxyethoxy)ethyl]-10H-phenothiazine (MEEPT, 1) which features a redox active phenothiazine core and an alkoxy chain to increase solubility in non-aqueous media. 1 acts as a catholyte material for a non-aqueous redox flow battery (RFB), and is miscible with non-aqueous organic solvents to provide electrolyte solutions with high concentration. In addition, 1 shows high current density and long duration cycling for further development of a non-aqueous RFB.¹⁾




Figure 1. Electrochemical and Spectral Properties of MEEPT/MEEPT⁺

- (a) Cyclic voltammogram of MEEPT at 10 mM in 0.1 M TBAPF₆ in DCM recorded at scan rates from 10 to 500 mV/s.
 (b) UV-vis spectra of MEEPT-SbCl₆ at 0.15 mM in acetonitrile for up to 24 h after dissolution. (These graphical materials were provided by Prof. Odom.)

Reference

- 1) High current density, long duration cycling of soluble organic active species for non-aqueous redox flow batteries
 J. D. Milshtein, A. P. Kaur, M. D. Casselman, J. A. Kowalski, S. Modekrutti, P. L. Zhang, N. H. Attanayake, C. F. Elliott, S. R. Parkin, C. Risko, F. R. Brushett, S. A. Odom, *Energy Environ. Sci.* **2016**, *9*, 3531.

TCI Related Products

M1531	4-Methacryloyloxy-2,2,6,6-tetramethylpiperidine 1-Oxyl Free Radical	1g	5g
H0865	4-Hydroxy-2,2,6,6-tetramethylpiperidine 1-Oxyl Free Radical (= TEMPOL)	5g	25g
B5642	Bis(2,2,6,6-tetramethyl-4-piperidyl-1-oxyl) Sebacate	1g	5g
A1343	4-Amino-2,2,6,6-tetramethylpiperidine 1-Oxyl Free Radical	1g	5g
V0137	2,2'-(2-Vinylanthracene-9,10-diylidene)dimalononitrile	1g	5g
V0136	2,2'-(2-Vinylanthracene-9,10-diylidene)bis(1,3-dithiole)	100mg	500mg

Glossary: Redox flow battery

Redox flow batteries (RFB) have long duration cycling by charge/discharge, which may have applications for grid level energy storage. RFB may be useful for large energy storage by increasing battery scale; however, it cannot be compact due to low energy density. Aqueous RFB's using vanadium ion and water-soluble organic active materials in particular have received much attention.^{1,2)} Alternatively, organic solvents (e.g. acetonitrile, carbonate) can be expected to improve solubility of organic active materials to increase energy density.³⁾

- 1) M. Skyllas-Kazacos, L. Cao, M. Kazacos, N. Kausar, A. Mousa, *ChemSusChem* **2016**, *9*, 1521. 2) E. S. Beh, D. De Porcellinis, R. L. Gracia, K. T. Xia, R. G. Gordon, M. J. Aziz, *ACS Energy Lett.* **2017**, *2*, 639. 3) J. Winsberg, T. Hagemann, T. Janoschka, M. D. Hager, U. S. Schubert, *Angew. Chem. Int. Ed.* **2017**, *56*, 686.

Lead Acetate Anhydrous Forming Perovskite under Anhydrous Condition

L0315 Lead(II) Acetate [for Perovskite precursor] (1)

1g 5g 25g

Perovskite solar cells have received much attention due to their increased efficiency, and are anticipated to be fabricated at lower costs in the future. The light absorbing layer in the solar cell consists of lead perovskites. It is well known that high quality perovskite precursor boosts the solar cell efficiency with reproducibility.¹⁾ Recently, the use of a lead acetate precursor was reported for several perovskite researches. Anhydrous lead acetate (1) allows for dry perovskite solar cell production, although lead acetate trihydrate is typically what is available. Lead acetate affords fast crystal growth of perovskites, and provides ultrasmooth pin-hole free perovskite film.²⁻⁷⁾



Scheme 1. Proposed formation mechanism of $\text{CH}_3\text{NH}_3\text{PbI}_3$ from Pb(OAc)_2 ²⁾

References

- 1) Reproducible fabrication of efficient perovskite-based solar cells: X-ray crystallographic studies on the formation of $\text{CH}_3\text{NH}_3\text{PbI}_3$ layers
A. Wakamiya, M. Endo, T. Sasamori, N. Tokitoh, Y. Ogomi, S. Hayase, Y. Murata, *Chem. Lett.* **2014**, 43, 711.
- 2) PCE >10%: Effect of different lead precursors on perovskite solar cell performance and stability
F. K. Aldibaja, L. Badia, E. Mas-Marzá, R. S. Sánchez, E. M. Barea, I. Mora-Sero, *J. Mater. Chem. A* **2015**, 3, 9194.
- 3) PCE >17%: High performance perovskite solar cell *via* multi-cycle low temperature processing of lead acetate precursor solutions
T. Singh, T. Miyasaka, *Chem. Commun.* **2016**, 52, 4784.
- 4) PCE 14%: Ultrasmooth organic–inorganic perovskite thin-film formation and crystallization for efficient planar heterojunction solar cells
W. Zhang, M. Saliba, D. T. Moore, S. K. Pathak, M. T. Hörantner, T. Stergiopoulos, S. D. Stranks, G. E. Eperon, J. A. Alexander-Webber, A. Abate, A. Sadhanala, S. Yao, Y. Chen, R. H. Friend, L. A. Estroff, U. Wiesner, H. J. Snaith, *Nat. Commun.* **2015**, 6, 6142.
- 5) PCE >18%: High-performance inverted planar heterojunction perovskite solar cells based on lead acetate precursor with efficiency exceeding 18%
L. Zhao, D. Luo, J. Wu, Q. Hu, W. Zhang, K. Chen, T. Liu, Y. Liu, Y. Zhang, F. Liu, T. P. Russell, H. J. Snaith, R. Zhu, Q. Gong, *Adv. Funct. Mater.* **2016**, 26, 3508.
- 6) PCE >13%: Pinhole-free perovskite films for efficient solar modules
W. Qiu, T. Merckx, M. Jaysankar, C. Masse de la Huerta, L. Rakocevic, W. Zhang, U. W. Paetzold, R. Gehlhaar, L. Froyen, J. Poortmans, D. Cheyuns, H. J. Snaith, P. Heremans, *Energy Environ. Sci.* **2016**, 9, 484.
- 7) PCE >14%: Chlorine incorporation for enhanced performance of planar perovskite solar cell based on lead acetate precursor
J. Qing, H.-T. Chandran, Y.-H. Cheng, X.-K. Liu, H.-W. Li, S.-W. Tsang, M.-F. Lo, C.-S. Lee, *ACS Appl. Mater. Interfaces* **2015**, 7, 23110.

TCI Related Products

L0279	Lead(II) Iodide (99.99%, trace metals basis) [for Perovskite precursor]	1g	5g	25g	100g	1kg
L0288	Lead(II) Bromide [for Perovskite precursor]			1g	5g	25g
L0291	Lead(II) Chloride (purified by sublimation) [for Perovskite precursor]				1g	5g
L0292	Lead(II) Chloride [for Perovskite precursor]			1g	5g	25g
M2556	Methylamine Hydroiodide (MAI), (Water <100 ppm) [for Perovskite precursor]		1g	5g	25g	100g
F0974	Formamidinium Hydroiodide (FAI), (Water <100 ppm) [for Perovskite precursor]			1g	5g	25g

Ready-to-use 4-Nitrophenyl Phosphate Solution for ELISA

N1109 4-Nitrophenyl Phosphate (Ready-to-use solution) [for ELISA] (1)

100mL

1 is supplied as a ready-to-use solution containing 4-nitrophenyl phosphate (pNPP) for ELISA. When **1** reacts with alkaline phosphatases, yellow colored soluble products appear. After terminating the reaction by adding NaOH aqueous solution, the absorbances of the reaction product are measured at 405 nm.

Direction for Use

The following steps are for a 96-well plate format.

1. Bring **1** to room temperature and mix it gently.
2. Add 100 μ L of **1** to each well.
3. Incubate the plate at room temperature for 30 minutes.
4. To terminate the reaction, add 100 μ L of 1 mol/L NaOH to each well.
5. Within 1 hour of terminating the reaction, measure the absorbance of each well at 405 nm.




Figure 1. Example of use with a 96-well plate

Reference

- 1) A. Voller, D. E. Bidwell, A. Bartlett, *Bull. World Health Organ.* **1976**, *53*, 55.

TCI Related Products

D4005 Disodium 4-Nitrophenyl Phosphate Hexahydrate [for Biochemical Research]
S0542 Sodium Hydroxide (1 mol/L in Water)

1g 5g
500mL

Anti- α Gal Polyclonal Antibody that can Detect the α Gal Epitope($\text{Gal}\alpha 1\text{-}3\text{Gal}$)

A3123 Anti- α Gal Polyclonal Antibody (Chicken) (1)

1 vial

Anti- α Gal antibody exists as a natural antibody in humans. Binding of this antibody to α Gal antigens (α Gal epitope) expressed on porcine xenograft surfaces are a major factor for determining engraft survival. Recently, it has been observed that therapeutic antibodies and cell processing material for reproductive medicine contain the α Gal epitope, which indicates the importance of rapid detection of α Gal epitope.

The anti- α Gal polyclonal antibody (1) has high specificity similar to the anti- α Gal monoclonal antibody, and it specifically recognizes the $\alpha 1\text{-}3\text{Gal}$ structure (Figure 1).




Figure 1. Specific binding to α Gal antigens by anti- α Gal monoclonal antibody Glycoconjugates coated on ELISA plates. Results following epitope and anti- α Gal antibodies incubation. 1st Ab were detected using appropriate secondary antibodies.

This product is for research purpose only.

TCI Related Products

A3144 Anti- α Gal Polyclonal Antibody Biotin Conjugate

1 vial


A3195 Anti- α Gal Chicken Polyclonal Antibody HRP Conjugate

1 vial

OCT4 Activator

00490 OAC1 (1)

10mg 50mg



OAC1 (**1**) was identified through high-throughput screening of a small molecule library as an OCT4-activating compound.¹⁾ **1** enhanced reprogramming efficiency of induced pluripotent stem (iPS) cells. Furthermore, **1** was used for direct-reprogramming of mouse fibroblasts into functional astrocytes.²⁾

1 also enhanced *ex vivo* expansion of human umbilical-cord blood hematopoietic stem and progenitor cells.³⁾ Homeobox protein, HOXB4, is essential for the **1**-mediated expansion.

This product is for research purpose only.


References

- 1) Identification of Oct4-activating compounds that enhance reprogramming efficiency
W. Li, E. Tian, Z.-X. Chen, G. Sun, P. Ye, S. Yang, D. Lu, J. Xie, T.-V. Ho, W. M. Tsark, C. Wang, D. A. Horne, A. D. Riggs, M. L. R. Yip, Y. Shi, *Proc. Natl. Acad. Sci. USA* **2012**, *109*, 20853.
- 2) Small-molecule-based lineage reprogramming creates functional astrocytes
E. Tian, G. Sun, G. Sun, J. Chao, P. Ye, C. Warden, A. D. Riggs, Y. Shi, *Cell Rep.* **2016**, *16*, 781.
- 3) Activation of OCT4 enhances *ex vivo* expansion of human cord blood hematopoietic stem and progenitor cells by regulating HOXB4 expression
X. Huang, M.-R. Lee, S. Cooper, G. Hangoc, K.-S. Hong, H.-M. Chung, H. E. Broxmeyer, *Leukemia* **2016**, *30*, 144.

AMP-Activated Protein Kinase (AMPK) Inhibitor

D5394 Dorsomorphin (1)

10mg 50mg



Dorsomorphin (**1**) is a potent inhibitor of AMP-activated protein kinase (AMPK).¹⁾ AMPK is inhibited by **1** with $K_i = 109$ nM. However, **1** does not significantly inhibit structurally related kinases, including spleen tyrosine kinase (SYK), zeta-chain-associated protein kinase (ZAPK), protein kinase A (PKA), protein kinase C θ (PKC θ), and Janus kinase (JAK).

Additionally, **1** inhibits bone morphogenetic protein (BMP) signaling.²⁾ **1** promotes self-renewal of human embryonic stem cells (hESCs).³⁾ Interestingly, **1** can support stem cell self-renewal over the long term (five or more passages).

This product is for research purpose only.

References

- 1) Role of AMP-activated protein kinase in mechanism of metformin action
G. Zhou, R. Myers, Y. Li, Y. Chen, X. Shen, J. Fenyk-Melody, M. Wu, J. Ventre, T. Doebber, N. Fujii, N. Musi, M. F. Hirshman, L. J. Goodyear, D. E. Moller, *J. Clin. Invest.* **2001**, *108*, 1167.
- 2) Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism
P. B. Yu, C. C. Hong, C. Sachidanandan, J. L. Babbitt, D. Y. Deng, S. A. Hoyng, H. Y. Lin, K. D. Bloch, R. T. Peterson, *Nat. Chem. Biol.* **2008**, *4*, 33.
- 3) Dorsomorphin promotes human embryonic stem cell self-renewal
R. Gonzalez, J. W. Lee, E. Y. Snyder, P. G. Schultz, *Angew. Chem. Int. Ed.* **2011**, *50*, 3439.

TCI Catalogs & Product Brochures

TCI has a wide variety of specific catalogs and product brochures. Most of them are available in PDF format and can be downloaded from our website. Please click the following links to pick up the catalogs and brochures you are interested in:



- » **Catalogs and Reagent Guides**
- » **Product Brochures**
- » **Pamphlets of Custom Synthesis**
- » **TCIMAIL (Quarterly Magazine)**

Access to www.TCIchemicals.com

Please visit our website!

Pamphlets of TCI Products

Antibodies and Related Reagents



This brochure contains all antibodies and related reagents including anti-carbohydrate antibodies, secondary antibodies, and detection reagents.

- **Anti-carbohydrate antibodies, secondary antibodies, anti-tag, anti-virus, and protein A for purified human antibodies are listed.**
- **Useful detection reagents and several ready-to-use solution reagents are listed.**

www.TCIchemicals.com/pdf/L3026E.pdf



Research Chemicals Catalog is now available



- ✓ Over 26,000 research chemicals
- ✓ Over 3,000 new products
- ✓ 1/3 unique TCI products

Request your free copies at
TCIchemicals.com/catalog-etm/

Ordering and Customer Service

TCI AMERICA

Tel : 800-423-8616 • 503-283-1681
Fax : 888-520-1075 • 503-283-1987
E-mail : Sales-US@TCIchemicals.com
Address : 9211 N. Harborside Street, Portland,
OR 97203, U.S.A.

East Coast Sales and Marketing Office

E-mail : Sales-US@TCIchemicals.com
Address : 222 Third Street, Cambridge,
MA 02142

Philadelphia Distribution Center

E-mail : Sales-US@TCIchemicals.com
Address : 121 Domoriah Drive, Montgomeryville,
PA 18936

TCI EUROPE N.V.

Tel : +32 (0)3 735 07 00
Fax : +32 (0)3 735 07 01
E-mail : Sales-EU@TCIchemicals.com
Address : Boerenveldseweg 6 - Haven 1063,
2070 Zwijndrecht, Belgium

TCI Deutschland GmbH

Tel : +49 (0)6196 64053-00
Fax : +49 (0)6196 64053-01
E-mail : Sales-DE@TCIchemicals.com
Address : Mergenthalerallee 79-81, D-65760 Eschborn,
Germany

Tokyo Chemical Industry UK Ltd.

Tel : +44 (0)1865 784560
Fax : +44 (0)1865 784561
E-mail : Sales-UK@TCIchemicals.com
Address : The Magdalen Centre, Robert Robinson Avenue
The Oxford Science Park, Oxford OX4 4GA, U.K.

TOKYO CHEMICAL INDUSTRY CO., LTD.

Tel : +81 (0)3-5640-8878
Fax : +81 (0)3-5640-8902
E-mail : globalbusiness@TCIchemicals.com
Address : 4-10-2, Nihonbashi-Honcho, Chuo-ku,
Tokyo 103-0023, Japan

梯希爱(上海)化成工业发展有限公司

Tel : 800-988-0390 • +86 (0)21-6712-1386
Fax : +86 (0)21-6712-1385
E-mail : Sales-CN@TCIchemicals.com
Address : 上海化学工业区普工路96号, 邮编201507

TCI Chemicals (India) Pvt. Ltd.

Tel : +91 (0)44-2262 0909
Fax : +91 (0)44-2262 8902
E-mail : Sales-IN@TCIchemicals.com
Address : Plot No. B-28, Phase II, 5th Cross Street, MEPZ-SEZ,
Tambaram, Chennai, Tamilnadu - 600045,
India

• The chemical, physical and toxicological properties of some chemicals have not been thoroughly investigated. Please handle with care.
• Chemicals itemized in this catalog are for testing or research purpose only. Therefore, please note those chemicals are not guaranteed in the user's favor relating to various problems under the Patent Law that might occur through their use.
• Availability or specification of the listed products are subject to change without prior notice.
• Reproduction forbidden without the prior written consent of Tokyo Chemical Industry Co., Ltd.